

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

CLARIFICATION ANNOUNCEMENT

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”) on a voluntary basis.

The Company has noted the letter dated February 12, 2024 (the “**Letter**”) from certain United States of America (“**U.S.**”) lawmakers to the selected U.S. government agencies, which, among others, mentioned the Company. The Company would like to clarify that the Company is not a subsidiary of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司), as wrongly stated in the Letter. The Company is an independent public company listed on the Main Board of The Stock Exchange of Hong Kong Limited and operates its business independently. While the Company fully supports regulatory reviews of its industry, the Company strongly opposes to any inaccurate statements and unfounded allegations against itself without proper consideration of the facts.

The Company would like to reiterate that it has not, does not and will not pose any national security risk to the U.S. or any other country. The Company has always abided and will continue to abide by the principles of compliant operations and the laws and regulations of the relevant jurisdictions where it conducts its operations and businesses. The Company remains strongly committed to service and contribute to the global healthcare community.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, February 14, 2024

*As at the date of this announcement, the board of directors of the Company (“**Directors**”) comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.*

* For identification purpose only